TOLEDO, Ohio – NAMSA, the world’s only Medical Research Organization (MRO) that accelerates medical device development through integrated laboratory testing, clinical research, and regulatory and reimbursement consulting services, announced today that it has been recognized for excellence in clinical research and honored for the third consecutive year as a 2019 “CRO Leadership Award” winner.
The CRO Leadership Awards are issued by Life Science Leader Magazine and are based on data gathered by Industry Standard Research, a full-service biotechnology market research firm. Recipients of this esteemed award are evaluated against 70+ Clinical Research Organizations (CROs) and selected based on feedback from Sponsor decision-makers who have utilized clinical research services within the last 18 months.
NAMSA was ranked as a CRO industry leader in the categories of: 1) Capabilities; 2) Compatibility; and 3) Quality, with top performance identified in the areas of Data Quality and Access, Meeting Project Timelines, Operational Excellence, Responsiveness and Innovative Solutions over the last three years.
“The CROs receiving an award this year are truly at the top of their class, and are deserving of the recognition they receive. Being a top performer in any of these categories shows a level of expertise and commitment to clinical trials and serving the needs of biotechnology companies and their patients,” stated Ed Miseta, Executive Editor, Life Science Leader.
“This honor is a result of our dedicated focus on providing high quality services and using client resources judiciously to deliver time and cost savings throughout the full medical device development continuum. By combining our scientific knowledge with NAMSA’s Medical Research Organization (MRO®) Approach, clients achieve clinical endpoints more quickly and are empowered to make effective decisions that accelerate the global delivery of life-changing medical technologies,” commented NAMSA President & CEO, John Gorski.
For over 50 years, NAMSA has partnered with thousands of global customers to provide the most critical research services required to accelerate time-to-market and reduce costs for medical device innovation and research. Consistently recognized as an industry leader, with an established track record of providing clients development savings of up to 23 months and $17M in costs, NAMSA is dedicated to partnering with manufacturers to bring novel medical technology to the marketplace in the most efficient manner possible.
NAMSA operates 13 offices throughout North America, Europe, Latin America, the Middle East and Asia, and employs over 1,000 highly-experienced laboratory testing, clinical research and regulatory and reimbursement consulting Associates.